Full name
A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), and Healthy Participants of Chinese and Japanese Descent (Part C)
NCT Number
NCT06576271
Geography
Non-US
Locations
United Kingdom
Primary Endpoints
- Parts A, B and C: Number of participants with non-serious adverse events and serious adverse events. Up to Week 52
- Parts A, B and C: Number of participants with clinically significant changes in physical examination, laboratory parameters, vital signs, and 12 lead electrocardiogram (ECG) findings. Up to Week 52
- Parts A, B and C: Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS). Up to Week 52
Order
3
Disease
Version
Phase
1
Status
Recruiting